Back to discover
Drug

Ipatasertib

In clinical development
ClassSerine/threonine-protein kinase AKT inhibitorEmerging researchLate-stage development
RxNorm1507790ChEMBLCHEMBL2177390UNII524Y3IB4HQ
1
Research papers
20
Active clinical trials
3
Protein targets
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Molecular Analysis for Therapy Choice (MATCH)

Clinical trial2026-07-31Results expected Q4 2026 · ClinicalTrials.gov

An Open-Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Study

Clinical trial2026-07-10Results expected Q1 2033 · ClinicalTrials.gov

Molecular Analysis for Combination Therapy Choice (ComboMATCH)

Clinical trial2026-07-09Results expected Q3 2030 · ClinicalTrials.gov

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS-BREAST CANCER)

Clinical trial2026-07-06Results expected Q2 2029 · ClinicalTrials.gov

A Phase IB and Randomized Phase II Trial of Megestrol Acetate With or Without Ipatasertib in Recurrent or Metastatic Endometrioid Endometrial Cancer

Clinical trial2026-07-02Results expected Q1 2027 · ClinicalTrials.gov

A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic Breast Cancer (Morpheus-panBC)

Clinical trial2026-06-17Results expected Q3 2030 · ClinicalTrials.gov

A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

Clinical trial2026-06-08Results expected Q1 2028 · ClinicalTrials.gov

MATCH Treatment Subprotocol Z1K: Ipatasertib in Patients With Tumors With AKT Mutations

Clinical trial2026-06-01Results posted · ClinicalTrials.gov

Phase 1/1b Study of AKT Inhibitor Ipatasertib With Chemoradiation for Locally Advanced Head and Neck Cancer

Clinical trial2026-05-18Results expected Q3 2027 · ClinicalTrials.gov

A Phase 2 Study of Ipatasertib in Combination With Pembrolizumab for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Clinical trial2026-05-13Results expected Q2 2027 · ClinicalTrials.gov

A Randomised, Open-label Phase II Study to Determine the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in Women With Triple-negative Breast Cancer

Clinical trial2026-05-08Results expected Q3 2026 · ClinicalTrials.gov

First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results.

Research2024-02-01Clinical cancer research : an official journal of the American Association for Cancer Research

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Ipatasertib
RxNorm CUI
1507790
ChEMBL ID
CHEMBL2177390
UNII
524Y3IB4HQ
Primary mechanism
Serine/threonine-protein kinase AKT inhibitor

Pharmacology & targets

3 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

RAC-beta serine/threonine-protein kinase
AKT2 · P31751
INHIBITORSerine/threonine-protein kinase AKT inhibitor
RAC-gamma serine/threonine-protein kinase
AKT3 · Q9Y243
INHIBITORSerine/threonine-protein kinase AKT inhibitor
RAC-alpha serine/threonine-protein kinase
AKT1 · P31749
INHIBITORSerine/threonine-protein kinase AKT inhibitor

Clinical trials

52 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
52
registered trials across all phases
LATEST COMPLETION 2025
20
Active studies
7
Recruiting
5
Late-stage (III+)
24
Completed
8
Discontinued
PHASE DISTRIBUTIONn = 52
Phase 115Phase 1 / 210Phase 222Phase 35

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

An Open-Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Study

RecruitingPH IIIHoffmann-La Rochen=1002033

Double-Blind Placebo-Controlled Randomized Phase III Trial of Fulvestrant and Ipatasertib as Treatment for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor

Active, not recruitingPH IIICanadian Cancer Trials Groupn=2502026

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

CompletedPH IIIKey trialHoffmann-La Rochen=1,1012024

A Phase III, Double-blind, Placebo-controlled, Randomized Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Patients With Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

CompletedPH IIIHoffmann-La Rochen=2422023

A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer

CompletedPH IIIHoffmann-La Rochen=5792023

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Phase Ib Study of Ipatasertib, an AKT Inhibitor, in Combination With Pertuzumab Plus Trastuzumab in Patients With PI3KCA-mutant, HER2-positive Locally Advanced or Metastatic Breast Cancer

CompletedPH ISOLTI Breast Cancer Research Groupn=172025

Continuous ReAssessment With Flexible ExTension in Rare Malignancies - CRAFT: The NCT-PMO-1602 Phase II Trial

CompletedPH IIGerman Cancer Research Centern=722024

A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy

CompletedPH IIHoffmann-La Rochen=5292024

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Hormone Receptor-Positive HER2-Negative Breast Cancer (MORPHEUS-HR+ Breast Cancer)

CompletedPH I/IIHoffmann-La Rochen=1442024

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

CompletedPH IIIKey trialHoffmann-La Rochen=1,1012024

MyTACTIC: An Open-Label Phase II Study Evaluating Targeted Therapies in Patients Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

CompletedPH IIGenentech, Inc.n=2522024

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results.

Clinical cancer research : an official journal of the American Association for Cancer Research · 2024 · 35 cites
Recent papers

First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results.

Clinical cancer research : an official journal of the American Association for Cancer Research · 2024 · 35 cites
Major research themes5
Antibodies, Monoclonal, Humanized1Bridged-Ring Compounds1Piperazines1Pyrimidines1Triple Negative Breast Neoplasms1
Journals, researchers & institutions
Top journals
  • Clinical cancer research : an official journal of the American Association for Cancer Research1
Leading researchers
  • Barrios CH1
  • Bondarenko I1
  • Boni V1
  • Chae Y1
  • Dent R1
  • Espinosa E1
  • Freitas-Junior R1
  • Huang X1
Leading institutions
free-text, unnormalised
  • Asan Medical Center1
  • Austin Hospital1
  • Barts Cancer Institute1
  • Baylor University Medical Center1
  • Breast Cancer Now Research Centre1
  • Christus Muguerza Clinica Vidriera1

Related drugs

2 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Atezolizumab

Studied across the same disease area as Ipatasertib in the shared literature.

1 shared disease1 shared paper
Paclitaxel

Studied across the same disease area as Ipatasertib in the shared literature.

1 shared disease1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials